董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samir N. Khleif | 男 | Director | 55 | 46.60万美元 | 22.13 | 2018-12-31 |
| Kenneth Berlin | 男 | President and Chief Executive Officer, Director | 54 | 未披露 | 34.83 | 2018-12-31 |
| Richard J. Berman | 男 | Director | 76 | 46.60万美元 | 未持股 | 2018-12-31 |
| David Sidransky | 男 | Chairman of our Board of Director | 58 | 59.57万美元 | 23.04 | 2018-12-31 |
| Roni Appel | 男 | Director | 52 | 46.60万美元 | 30.23 | 2018-12-31 |
| James Patton | 男 | Vice Chairman of our Board of Director | 61 | 53.09万美元 | 41.06 | 2018-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Molly Henderson | 女 | Chief Financial Officer, Executive Vice President and Corporate Secretary | 47 | 未披露 | 0.50 | 2018-12-31 |
| Kenneth Berlin | 男 | President and Chief Executive Officer, Director | 54 | 未披露 | 34.83 | 2018-12-31 |
| Andres Gutierrez | 男 | Chief Medical Officer and Executive Vice President | 58 | 未披露 | 未持股 | 2018-12-31 |
| Robert G. Petit | 男 | Chief Scientific Officer and Executive Vice President | 59 | 186.06万美元 | 51.97 | 2018-12-31 |
董事简历
中英对照 | 中文 | 英文- Samir N. Khleif
-
SamirN.Khleif自2014年10月以来一直担任我们的董事会成员。他目前担任State of Georgia Cancer Center、Georgia Regents University Cancer Center和the Cancer Service Line的董事。Khleif博士曾任新华保险癌症疫苗科科长，也曾担任领导肿瘤学关键途径倡议的FDA专员特别助理。Khleif博士是佐治亚州Research Alliance杰出的癌症科学家和临床医生，拥有医学、生物化学和分子生物学教授职位，并在佐治亚州摄政大学（Georgia Regents University）研究生学习。乔治亚摄政大学癌症中心的Khleif博士的研究计划专注于了解癌症诱导的免疫抑制的机制，并将这些知识用于开发针对癌症的新型免疫疗法和疫苗。他的研究小组设计并执行了一些针对癌细胞特定遗传变化的首批癌症疫苗临床试验。他领导了许多开发生物标记物和在临床试验中集成生物标记物的国家努力和委员会，包括AACR-新华保险-FDA癌症生物标记物合作和ASCO替代临床试验设计。Khleif博士是许多关于肿瘤免疫学和生物标志物过程发展的书籍章节和科学文章的作者，他是两本癌症治疗学、肿瘤免疫学和癌症疫苗教科书的编辑。Khleif博士入选美国临床研究学会，获得美国国家癌症研究所主任金星奖，美国国家卫生研究院功绩奖，美国公共卫生服务表彰奖章，以及他最近被任命到the Institute of Medicine National Cancer Policy Forum。
Samir N. Khleif has served as a member of our Board of Directors since October 2014. He currently serves as the Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center and the Cancer Service Line. Dr. Khleif was formerly Chief of the Cancer Vaccine Section at the NCI, and also served as a Special Assistant to the Commissioner of the FDA leading the Critical Path Initiative for oncology. Dr. Khleif is a Georgia Research Alliance Distinguished Cancer Scientist and Clinician and holds a professorship in Medicine, Biochemistry and Molecular Biology, and Graduate Studies at Georgia Regents University. Dr. Khleif’s research program at Georgia Regents University Cancer Center focuses on understanding the mechanisms of cancer-induced immune suppression, and utilizing this knowledge for the development of novel immune therapeutics and vaccines against cancer. His research group designed and performed some of the first cancer vaccine clinical trials targeting specific genetic changes in cancer cells. He led many national efforts and committees on the development of biomarkers and integration of biomarkers in clinical trials, including the AACR-NCI-FDA Cancer Biomarker Collaborative and the ASCO Alternative Clinical Trial Design. Dr. Khleif is the author of many book chapters and scientific articles on tumor immunology and biomarkers process development, and he is the editor for two textbooks on cancer therapeutics, tumor immunology, and cancer vaccines. Dr. Khleif was inducted into the American Society for Clinical Investigation, received the National Cancer Institute’s Director Golden Star Award, the National Institutes of Health Award for Merit, the Commendation Medal of the US Public Health Service, and he was recently appointed to the Institute of Medicine National Cancer Policy Forum. - SamirN.Khleif自2014年10月以来一直担任我们的董事会成员。他目前担任State of Georgia Cancer Center、Georgia Regents University Cancer Center和the Cancer Service Line的董事。Khleif博士曾任新华保险癌症疫苗科科长，也曾担任领导肿瘤学关键途径倡议的FDA专员特别助理。Khleif博士是佐治亚州Research Alliance杰出的癌症科学家和临床医生，拥有医学、生物化学和分子生物学教授职位，并在佐治亚州摄政大学（Georgia Regents University）研究生学习。乔治亚摄政大学癌症中心的Khleif博士的研究计划专注于了解癌症诱导的免疫抑制的机制，并将这些知识用于开发针对癌症的新型免疫疗法和疫苗。他的研究小组设计并执行了一些针对癌细胞特定遗传变化的首批癌症疫苗临床试验。他领导了许多开发生物标记物和在临床试验中集成生物标记物的国家努力和委员会，包括AACR-新华保险-FDA癌症生物标记物合作和ASCO替代临床试验设计。Khleif博士是许多关于肿瘤免疫学和生物标志物过程发展的书籍章节和科学文章的作者，他是两本癌症治疗学、肿瘤免疫学和癌症疫苗教科书的编辑。Khleif博士入选美国临床研究学会，获得美国国家癌症研究所主任金星奖，美国国家卫生研究院功绩奖，美国公共卫生服务表彰奖章，以及他最近被任命到the Institute of Medicine National Cancer Policy Forum。
- Samir N. Khleif has served as a member of our Board of Directors since October 2014. He currently serves as the Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center and the Cancer Service Line. Dr. Khleif was formerly Chief of the Cancer Vaccine Section at the NCI, and also served as a Special Assistant to the Commissioner of the FDA leading the Critical Path Initiative for oncology. Dr. Khleif is a Georgia Research Alliance Distinguished Cancer Scientist and Clinician and holds a professorship in Medicine, Biochemistry and Molecular Biology, and Graduate Studies at Georgia Regents University. Dr. Khleif’s research program at Georgia Regents University Cancer Center focuses on understanding the mechanisms of cancer-induced immune suppression, and utilizing this knowledge for the development of novel immune therapeutics and vaccines against cancer. His research group designed and performed some of the first cancer vaccine clinical trials targeting specific genetic changes in cancer cells. He led many national efforts and committees on the development of biomarkers and integration of biomarkers in clinical trials, including the AACR-NCI-FDA Cancer Biomarker Collaborative and the ASCO Alternative Clinical Trial Design. Dr. Khleif is the author of many book chapters and scientific articles on tumor immunology and biomarkers process development, and he is the editor for two textbooks on cancer therapeutics, tumor immunology, and cancer vaccines. Dr. Khleif was inducted into the American Society for Clinical Investigation, received the National Cancer Institute’s Director Golden Star Award, the National Institutes of Health Award for Merit, the Commendation Medal of the US Public Health Service, and he was recently appointed to the Institute of Medicine National Cancer Policy Forum.
- Kenneth Berlin
-
Kenneth Berlin自2018年4月起担任我们的总裁兼首席执行官兼董事会成员。在加入Advaxis之前，Berlin先生自2009年11月起担任Rosetta Genomics的总裁兼首席执行官。在加入Rosetta Genomics之前，Berlin先生是强生公司公司Veridex，LLC的全球总经理。在Veridex，随着Veridex从研发实体过渡到肿瘤诊断产品和服务的商业提供商，他将公司发展到100多名员工，推出了三种癌症诊断产品，领导了对其细胞诊断合作伙伴的收购，并实现了销售的大幅增长。Berlin先生于1994年加入强生公司，并担任了6年的公司法律顾问。从2001年到2004年，他曾担任Pharmaceuticals Group的Vice President、许可和新业务开发，从2004年到2007年，他曾担任Ortho-Clinical Diagnostics公司的全球Vice President、特许经营开发。Berlin先生拥有普林斯顿大学（Princeton University）的A.B.学位和加州大学洛杉矶分校（University of California Los Angeles School of Law）的法学博士学位。
Kenneth Berlin has served as our President and Chief Executive Officer and a member of our Board of Directors since April 2018. Prior to joining Advaxis, Mr. Berlin served as President and Chief Executive Officer of Rosetta Genomics since November 2009. Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. At Veridex he grew the organization to over 100 employees, launched three cancer diagnostic products, led the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from an R&D entity to a commercial provider of oncology diagnostic products and services. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics. Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California Los Angeles School of Law. - Kenneth Berlin自2018年4月起担任我们的总裁兼首席执行官兼董事会成员。在加入Advaxis之前，Berlin先生自2009年11月起担任Rosetta Genomics的总裁兼首席执行官。在加入Rosetta Genomics之前，Berlin先生是强生公司公司Veridex，LLC的全球总经理。在Veridex，随着Veridex从研发实体过渡到肿瘤诊断产品和服务的商业提供商，他将公司发展到100多名员工，推出了三种癌症诊断产品，领导了对其细胞诊断合作伙伴的收购，并实现了销售的大幅增长。Berlin先生于1994年加入强生公司，并担任了6年的公司法律顾问。从2001年到2004年，他曾担任Pharmaceuticals Group的Vice President、许可和新业务开发，从2004年到2007年，他曾担任Ortho-Clinical Diagnostics公司的全球Vice President、特许经营开发。Berlin先生拥有普林斯顿大学（Princeton University）的A.B.学位和加州大学洛杉矶分校（University of California Los Angeles School of Law）的法学博士学位。
- Kenneth Berlin has served as our President and Chief Executive Officer and a member of our Board of Directors since April 2018. Prior to joining Advaxis, Mr. Berlin served as President and Chief Executive Officer of Rosetta Genomics since November 2009. Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. At Veridex he grew the organization to over 100 employees, launched three cancer diagnostic products, led the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from an R&D entity to a commercial provider of oncology diagnostic products and services. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics. Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.
- Richard J. Berman
-
RichardJ.Berman于2015年1月成为我们的董事会成员，并担任董事会首席董事，审计委员会主席以及薪酬委员会和提名与治理委员会的成员。Berman先生的商业生涯跨越了超过35年的风险投资，高级管理和并购经验。Berman先生曾担任十多家上市和私营公司的董事和/或高级管理人员。从2006年到2011年，他曾担任National Investment Managers公司（公司拥有120亿美元的养老金管理资产）的主席。Berman先生目前是四家上市公司的董事:Cryoport Inc.，ComSovereign Holding Corp.，BioVie，Inc.和Cuentas，Inc.。在过去的十年里，他曾在5家市值超过10亿美元的公司-Cryoport，Advaxis，Exide，Internet Commerce Corporation和Ontrak Catasys的董事会任职。此前，伯曼曾在高盛（Goldman Sachs）工作，是银行家信托公司（Bankers Trust Company）的高级副总裁，他在该公司创立了并购和杠杆收购部门，上世纪80年代，他通过合并Prestolite创建了世界上最大的电池公司，通用电池公司（General Battery）和Exide组建了Exide Technologies（Xide）；通过开发五栋大楼，帮助创建了现在的SOHO；并为超过40亿美元的并购交易提供咨询。他是纽约大学斯特恩商学院（the Stern School of Business of NYU）的前任董事，在那里他获得学士学位和工商管理硕士学位。他也分别拥有Boston College和Hague Academy of International Law的美国和外国法律学位。
Richard J. Berman became a member of our board of directors in January 2015 and serves as Lead Director, Chairman of the Audit Committee and member of the Compensation Committee and Nomination and Governance Committee of our board of directors. Mr. Berman’s business career spans over 35 years of venture capital, senior management and merger & acquisitions experience. Mr. Berman has served as a director and/or officer of over a dozen public and private companies. From 2006 to 2011 he was Chairman of National Investment Managers, a company with $12 billion in pension administration assets. Mr. Berman is currently a director of four publicly traded companies: Cryoport Inc., Comsovereign Holding Corp., BioVie, Inc. and Cuentas, Inc. Over the last decade he has served on the board of 5 companies that have reached over $1 billion in market capitalization - Cryoport, Advaxis, EXIDE, Internet Commerce Corporation, and Ontrak Catasys. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world in the 1980’s by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE); helped to create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions. He is a past Director of the Stern School of Business of NYU where he obtained his BS and MBA. He also has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively. - RichardJ.Berman于2015年1月成为我们的董事会成员，并担任董事会首席董事，审计委员会主席以及薪酬委员会和提名与治理委员会的成员。Berman先生的商业生涯跨越了超过35年的风险投资，高级管理和并购经验。Berman先生曾担任十多家上市和私营公司的董事和/或高级管理人员。从2006年到2011年，他曾担任National Investment Managers公司（公司拥有120亿美元的养老金管理资产）的主席。Berman先生目前是四家上市公司的董事:Cryoport Inc.，ComSovereign Holding Corp.，BioVie，Inc.和Cuentas，Inc.。在过去的十年里，他曾在5家市值超过10亿美元的公司-Cryoport，Advaxis，Exide，Internet Commerce Corporation和Ontrak Catasys的董事会任职。此前，伯曼曾在高盛（Goldman Sachs）工作，是银行家信托公司（Bankers Trust Company）的高级副总裁，他在该公司创立了并购和杠杆收购部门，上世纪80年代，他通过合并Prestolite创建了世界上最大的电池公司，通用电池公司（General Battery）和Exide组建了Exide Technologies（Xide）；通过开发五栋大楼，帮助创建了现在的SOHO；并为超过40亿美元的并购交易提供咨询。他是纽约大学斯特恩商学院（the Stern School of Business of NYU）的前任董事，在那里他获得学士学位和工商管理硕士学位。他也分别拥有Boston College和Hague Academy of International Law的美国和外国法律学位。
- Richard J. Berman became a member of our board of directors in January 2015 and serves as Lead Director, Chairman of the Audit Committee and member of the Compensation Committee and Nomination and Governance Committee of our board of directors. Mr. Berman’s business career spans over 35 years of venture capital, senior management and merger & acquisitions experience. Mr. Berman has served as a director and/or officer of over a dozen public and private companies. From 2006 to 2011 he was Chairman of National Investment Managers, a company with $12 billion in pension administration assets. Mr. Berman is currently a director of four publicly traded companies: Cryoport Inc., Comsovereign Holding Corp., BioVie, Inc. and Cuentas, Inc. Over the last decade he has served on the board of 5 companies that have reached over $1 billion in market capitalization - Cryoport, Advaxis, EXIDE, Internet Commerce Corporation, and Ontrak Catasys. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world in the 1980’s by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE); helped to create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions. He is a past Director of the Stern School of Business of NYU where he obtained his BS and MBA. He also has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.
- David Sidransky
-
David Sidransky博士,目前担任约翰·霍普金斯大学头颈部癌症研究部主任、耳鼻喉科—头颈部外科教授、细胞与分子医学教授以及泌尿科及遗传学教授。Sidransky博士目前亦担任约翰霍普金斯肿瘤中心的肿瘤科教授。从1984年至1988年,Sidransky博士在美国贝勒大学医学院工作,并取得其医学博士学位,随后继续担任内科实习生及驻院医生,及担任内科首席驻院医生直至1988年6月。从1988年7月至1992年6月,Sidransky博士在约翰·霍普金斯大学及医院完成肿瘤科研究生课程,随后于1992年7月获委任为教师。Sidransky博士于1981年6月毕业于美国布兰迪斯大学,获得化学理学士学位。Sidransky博士是美国癌症研究协会及美国临床肿瘤学协会的现任会员。彼曾为美国国家癌症研究所下属多个工作组(包括发展诊断工作组及癌症预防及控制工作组)的成员。Sidransky博士亦获得美国内科医学委员会及美国肿瘤医学委员会的认证。此外,Sidransky博士目前参与美国国家癌症研究所国家科学顾问委员会。彼为Champions Oncology, Inc.(纳斯达克:CSBR)的创始人,目前为董事会领导。彼为Galmed Pharmaceuticals Ltd.(纳斯达克:GLMD)董事、Orgenesis Inc.(纳斯达克:ORGS)董事、Advaxis, Inc.(纳斯达克:ADXS)主席及Ayala Pharmaceuticals, Inc.(纳斯达克:AYLA)主席。彼亦为空服员医学研究基金会(Flight Attendants Medical Research Foundation)及囊癌研究(Adenocystic Carcinoma Research)的MAB主席。Sidransky博士获得了许多荣誉,如以色列癌症研究基金奥瑟曼奖(Israel Cancer Research Fund Osserman Award)、AACR — Richardand Hinda Rosenthal Foundation Award、巴伊兰大学杜比高密奖(Toby Comet Award Bar Ilan University)及AACR Team Award Theme Circulating DNA。截至本公告日期,彼于专业期刊上曾发表逾550篇文章、撰写45篇书籍章节、评述及评论以及为28项专利的发明者。于2021年3月31日获委任为亚盛医药集团独立非执行董事。
David Sidransky has served as a director since his appointment on July 18 2013. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994 Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over 460 peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, LLC, Roche, Amgen Inc. and Veridex, LLC a Johnson & Johnson diagnostic company, among others and is currently on the board of directors of Galmed and Rosetta Genomics Ltd. and chairs the board of directors of Advaxis and Champions Oncology, Inc. Dr. Sidransky served as Director from 2005 until 2008 of the American Association for Cancer Research (AACR). In 2006 and 2007 he was the chairperson of AACR International Conferences on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Award from the American Association of Cancer Research. Dr. Sidransky received his BS in Chemistry from Brandies University and his medical degree from Baylor College of medicine where he also completed his residency in internal medicine. His specialty in Medical Oncology was completed at Johns Hopkins University and Hospital. - David Sidransky博士,目前担任约翰·霍普金斯大学头颈部癌症研究部主任、耳鼻喉科—头颈部外科教授、细胞与分子医学教授以及泌尿科及遗传学教授。Sidransky博士目前亦担任约翰霍普金斯肿瘤中心的肿瘤科教授。从1984年至1988年,Sidransky博士在美国贝勒大学医学院工作,并取得其医学博士学位,随后继续担任内科实习生及驻院医生,及担任内科首席驻院医生直至1988年6月。从1988年7月至1992年6月,Sidransky博士在约翰·霍普金斯大学及医院完成肿瘤科研究生课程,随后于1992年7月获委任为教师。Sidransky博士于1981年6月毕业于美国布兰迪斯大学,获得化学理学士学位。Sidransky博士是美国癌症研究协会及美国临床肿瘤学协会的现任会员。彼曾为美国国家癌症研究所下属多个工作组(包括发展诊断工作组及癌症预防及控制工作组)的成员。Sidransky博士亦获得美国内科医学委员会及美国肿瘤医学委员会的认证。此外,Sidransky博士目前参与美国国家癌症研究所国家科学顾问委员会。彼为Champions Oncology, Inc.(纳斯达克:CSBR)的创始人,目前为董事会领导。彼为Galmed Pharmaceuticals Ltd.(纳斯达克:GLMD)董事、Orgenesis Inc.(纳斯达克:ORGS)董事、Advaxis, Inc.(纳斯达克:ADXS)主席及Ayala Pharmaceuticals, Inc.(纳斯达克:AYLA)主席。彼亦为空服员医学研究基金会(Flight Attendants Medical Research Foundation)及囊癌研究(Adenocystic Carcinoma Research)的MAB主席。Sidransky博士获得了许多荣誉,如以色列癌症研究基金奥瑟曼奖(Israel Cancer Research Fund Osserman Award)、AACR — Richardand Hinda Rosenthal Foundation Award、巴伊兰大学杜比高密奖(Toby Comet Award Bar Ilan University)及AACR Team Award Theme Circulating DNA。截至本公告日期,彼于专业期刊上曾发表逾550篇文章、撰写45篇书籍章节、评述及评论以及为28项专利的发明者。于2021年3月31日获委任为亚盛医药集团独立非执行董事。
- David Sidransky has served as a director since his appointment on July 18 2013. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994 Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over 460 peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, LLC, Roche, Amgen Inc. and Veridex, LLC a Johnson & Johnson diagnostic company, among others and is currently on the board of directors of Galmed and Rosetta Genomics Ltd. and chairs the board of directors of Advaxis and Champions Oncology, Inc. Dr. Sidransky served as Director from 2005 until 2008 of the American Association for Cancer Research (AACR). In 2006 and 2007 he was the chairperson of AACR International Conferences on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Award from the American Association of Cancer Research. Dr. Sidransky received his BS in Chemistry from Brandies University and his medical degree from Baylor College of medicine where he also completed his residency in internal medicine. His specialty in Medical Oncology was completed at Johns Hopkins University and Hospital.
- Roni Appel
-
Roni Appel，自2004年11月起担任我们公司的董事会成员。自2006年1月起，他担任我们公司的总裁兼首席执行官；从2004年11月直到他2006年9月辞任本公司财务总监，一直担任秘书及财务总监；2006年12月15日出任我们公司的总裁、首席执行官兼秘书。2006年12月15日至2007年12月，他担任我们公司的顾问。阿佩尔先生现任自雇顾问。此前，从2008年至2013年1月31日，他曾担任Anima Cell Metrology有限公司的首席执行官。从1999年到2004年，他的LV Equity Partners公司和 LibertyView Equity Partners公司的合伙人兼董事总经理。从1998年直到1999年，他担任美洲金融服务公司业务发展部董事。从1994至1998年，他是一名律师，并获得了在哥伦比亚大学的工商管理硕士学位。阿佩尔先生长期任职于我们公司，他在早期阶段生物技术企业的创业投资生涯使他有资格他担任我们公司的董事。
Roni Appel has served as a member of our Board of Directors since November 2004. He was our President and Chief Executive Officer from January 1 2006 and Secretary and Chief Financial Officer from November 2004 until he resigned as our Chief Financial Officer on September 7 2006 and as our President, Chief Executive Officer and Secretary on December 15 2006. From December 15 2006 to December 2007 Mr. Appel served as a consultant to us. Mr. Appel currently is a self-employed consultant. Previously, he served as Chief Executive Officer of Anima Cell Metrology Ltd., from 2008 through January 31 2013. From 1999 to 2004 he was a partner and managing director of LV Equity Partners f/k/a LibertyView Equity Partners. From 1998 until 1999 he was a director of business development at Americana Financial Services, Inc. From 1994 to 1998 he was an attorney and completed his M.B.A at Columbia University. Mr. Appel's longstanding service with us and his entrepreneurial investment career in early stage biotech businesses qualify him to serve as our director. - Roni Appel，自2004年11月起担任我们公司的董事会成员。自2006年1月起，他担任我们公司的总裁兼首席执行官；从2004年11月直到他2006年9月辞任本公司财务总监，一直担任秘书及财务总监；2006年12月15日出任我们公司的总裁、首席执行官兼秘书。2006年12月15日至2007年12月，他担任我们公司的顾问。阿佩尔先生现任自雇顾问。此前，从2008年至2013年1月31日，他曾担任Anima Cell Metrology有限公司的首席执行官。从1999年到2004年，他的LV Equity Partners公司和 LibertyView Equity Partners公司的合伙人兼董事总经理。从1998年直到1999年，他担任美洲金融服务公司业务发展部董事。从1994至1998年，他是一名律师，并获得了在哥伦比亚大学的工商管理硕士学位。阿佩尔先生长期任职于我们公司，他在早期阶段生物技术企业的创业投资生涯使他有资格他担任我们公司的董事。
- Roni Appel has served as a member of our Board of Directors since November 2004. He was our President and Chief Executive Officer from January 1 2006 and Secretary and Chief Financial Officer from November 2004 until he resigned as our Chief Financial Officer on September 7 2006 and as our President, Chief Executive Officer and Secretary on December 15 2006. From December 15 2006 to December 2007 Mr. Appel served as a consultant to us. Mr. Appel currently is a self-employed consultant. Previously, he served as Chief Executive Officer of Anima Cell Metrology Ltd., from 2008 through January 31 2013. From 1999 to 2004 he was a partner and managing director of LV Equity Partners f/k/a LibertyView Equity Partners. From 1998 until 1999 he was a director of business development at Americana Financial Services, Inc. From 1994 to 1998 he was an attorney and completed his M.B.A at Columbia University. Mr. Appel's longstanding service with us and his entrepreneurial investment career in early stage biotech businesses qualify him to serve as our director.
- James Patton
-
James Patton， 自2002年2月起担任我们公司的董事会；自2002年2月至2002年11月，担任我们公司的行政总裁；2004年11月至2005年12月31日，担任我们公司的董事会主席。自2006年1月至2013年8月18日，他留任董事一职。于2013年8月19日，巴顿博士获委任为本公司的董事会主席。自1999年2月起，巴顿博士担任千年肿瘤学管理公司（该公司提供放射肿瘤学领域的管理和咨询服务）的副总裁。自2006年10月起，巴顿博士一直担任邓迪财富美国公司（一家家族共同基金）的受托人。2011年至今，他担任VAL健康公司（一家医疗咨询公司）的创办人兼董事长。此外，自1999年以来，他担任Comprehensive Oncology Care公司的总裁，这是一家在宾夕法尼亚州艾克斯顿拥有并经营癌症治疗设施的公司，直到2008年它被销售。从1999年2月至2003年9月，巴顿博士担任LibertyView Equity Partners SBIC公司的顾问，这是一家总部设在新泽西州泽西城的风险投资基金。从2000年7月至2002年12月，巴顿博士担任Pinpoint Data公司的董事。从2000年2月至2000年11月，巴顿博士担任Healthware Solutions公司的董事。从2000年6月至2003年6月，巴顿博士担任LifeStar Response公司的董事。他持有密歇根大学的学士学位、宾夕法尼亚医学院的医学博士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。巴顿博士是一名罗伯特·伍德·约翰逊基金会的临床学者。他先后发表关于研究人类遗传学、医学诊断测试性能和经济性分析领域的科研论文。巴顿博士担任投资生命科学公司基金的顾问及托管人的经验，为他提供了让我们公司受益的所有观点。此外，巴顿博士的医学经验和担任其他生命科学公司董事兼负责人的经验使巴顿博士特别有资格担任我们公司的董事兼非执行董事长。
James Patton currently serves as the Vice Chairman of our Board of Directors, has served as the Chairman of our Board and has been a member of our Board of Directors since February 2002. Furthermore, Dr. Patton was the Chairman of our Board of Directors from November 2004 until December 31 2005 and was our Chief Executive Officer from February 2002 to November 2002. Since February 1999 Dr. Patton has been the Vice President of Millennium Oncology Management, Inc., which is a consulting company in the field of oncology services delivery. Dr. Patton was a trustee of Dundee Wealth US, a mutual fund family, from October 2006 through September 2014. He is a founder and has been chairman of VAL Health, LLC, a health care consultancy, from 2011 to the present. In addition, he was President of Comprehensive Oncology Care, LLC since 1999 a company that owned and operated a cancer treatment facility in Exton, Pennsylvania until its sale in 2008. From February 1999 to September 2003 Dr. Patton also served as a consultant to LibertyView Equity Partners SBIC, LP, a venture capital fund based in Jersey City, New Jersey. From July 2000 to December 2002 Dr. Patton served as a director of Pinpoint Data Corp. From February 2000 to November 2000 Dr. Patton served as a director of Healthware Solutions. From June 2000 to June 2003 Dr. Patton served as a director of LifeStar Response. He earned his B.S. from the University of Michigan, his Medical Doctorate from Medical College of Pennsylvania, and his M.B.A. from Penn’s Wharton School. Dr. Patton was also a Robert Wood Johnson Foundation Clinical Scholar. He has published papers regarding scientific research in human genetics, diagnostic test performance and medical economic analysis. - James Patton， 自2002年2月起担任我们公司的董事会；自2002年2月至2002年11月，担任我们公司的行政总裁；2004年11月至2005年12月31日，担任我们公司的董事会主席。自2006年1月至2013年8月18日，他留任董事一职。于2013年8月19日，巴顿博士获委任为本公司的董事会主席。自1999年2月起，巴顿博士担任千年肿瘤学管理公司（该公司提供放射肿瘤学领域的管理和咨询服务）的副总裁。自2006年10月起，巴顿博士一直担任邓迪财富美国公司（一家家族共同基金）的受托人。2011年至今，他担任VAL健康公司（一家医疗咨询公司）的创办人兼董事长。此外，自1999年以来，他担任Comprehensive Oncology Care公司的总裁，这是一家在宾夕法尼亚州艾克斯顿拥有并经营癌症治疗设施的公司，直到2008年它被销售。从1999年2月至2003年9月，巴顿博士担任LibertyView Equity Partners SBIC公司的顾问，这是一家总部设在新泽西州泽西城的风险投资基金。从2000年7月至2002年12月，巴顿博士担任Pinpoint Data公司的董事。从2000年2月至2000年11月，巴顿博士担任Healthware Solutions公司的董事。从2000年6月至2003年6月，巴顿博士担任LifeStar Response公司的董事。他持有密歇根大学的学士学位、宾夕法尼亚医学院的医学博士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。巴顿博士是一名罗伯特·伍德·约翰逊基金会的临床学者。他先后发表关于研究人类遗传学、医学诊断测试性能和经济性分析领域的科研论文。巴顿博士担任投资生命科学公司基金的顾问及托管人的经验，为他提供了让我们公司受益的所有观点。此外，巴顿博士的医学经验和担任其他生命科学公司董事兼负责人的经验使巴顿博士特别有资格担任我们公司的董事兼非执行董事长。
- James Patton currently serves as the Vice Chairman of our Board of Directors, has served as the Chairman of our Board and has been a member of our Board of Directors since February 2002. Furthermore, Dr. Patton was the Chairman of our Board of Directors from November 2004 until December 31 2005 and was our Chief Executive Officer from February 2002 to November 2002. Since February 1999 Dr. Patton has been the Vice President of Millennium Oncology Management, Inc., which is a consulting company in the field of oncology services delivery. Dr. Patton was a trustee of Dundee Wealth US, a mutual fund family, from October 2006 through September 2014. He is a founder and has been chairman of VAL Health, LLC, a health care consultancy, from 2011 to the present. In addition, he was President of Comprehensive Oncology Care, LLC since 1999 a company that owned and operated a cancer treatment facility in Exton, Pennsylvania until its sale in 2008. From February 1999 to September 2003 Dr. Patton also served as a consultant to LibertyView Equity Partners SBIC, LP, a venture capital fund based in Jersey City, New Jersey. From July 2000 to December 2002 Dr. Patton served as a director of Pinpoint Data Corp. From February 2000 to November 2000 Dr. Patton served as a director of Healthware Solutions. From June 2000 to June 2003 Dr. Patton served as a director of LifeStar Response. He earned his B.S. from the University of Michigan, his Medical Doctorate from Medical College of Pennsylvania, and his M.B.A. from Penn’s Wharton School. Dr. Patton was also a Robert Wood Johnson Foundation Clinical Scholar. He has published papers regarding scientific research in human genetics, diagnostic test performance and medical economic analysis.
高管简历
中英对照 | 中文 | 英文- Molly Henderson
Molly Henderson，她于2015年6月8日担任Advaxis, Inc.首席财务官和公司秘书。从2008年5月到2013年8月，她担任VirtualScopics, Inc.（制药、生物技术和医疗设备行业的成像解决方案上市供应商）的业务和财务总监和高级副总裁。从2003年5月到2008年5月，她担任公司的首席财务官。主要职责包括提供战略方向、监督所有战略、合同、法律、知识产权、商业和金融相关的问题，以及确保遵守金融和证券交易委员会报告要求。此外，她负责公司的投资者关系，准备和协调所有VirtualScopics公司的外部通信，包括新闻公告。她经常访问纽约和美国其它主要城市，进行路演以及频繁的公司演讲、公司的技术关键生命科学投资者会议。从2013年到2015年，她的家人搬到了欧洲。职业生涯早期，她担任Ultralife, Inc.（上市高性能锂电池解决方案供应商）的公司财务总监。任职Ultralife之前，她曾担任PricewaterhouseCoopers LLP的审计部门经理。她获得the State University of New York（位于水牛城）的学士学位和工商管理硕士学位。
Molly Henderson was appointed as Advaxis, Inc. Chief Financial Officer, Executive Vice President and Corporate Secretary in June 2018. Prior to assuming her position at Advaxis, Ms. Henderson was a freelance consultant, as well as the Chairman and partial owner of WUJU, LLC, a consumer products company, from August 2016 to June 2018. Prior to that, Ms. Henderson was Chief Financial Officer at Iovance Biotherapeutics, Inc. formerly Lion Biotechnologies, Inc. from June 2015 through August 2016. Ms. Henderson also served as the Chief Business and Financial Officer, Senior Vice President of VirtualScopics, Inc., a public company provider of imaging solutions to the pharmaceutical, biotechnology, and medical device industries, from May 2008 to August 2013 and as that company's Chief Financial Officer from May 2003 to May 2008. From 2013 to 2015 Ms. Henderson relocated her family to Europe, during which time Ms. Henderson advised start-up companies in Switzerland. Earlier in her career, Ms. Henderson served as the Corporate Controller of Ultralife, Inc., a publicly-held provider of high performance lithium battery solutions. Prior to Ultralife, Ms. Henderson was a Manager in the audit division of PricewaterhouseCoopers LLP. Ms. Henderson received her M.B.A. and B.S. degrees from the State University of New York at Buffalo.- Molly Henderson，她于2015年6月8日担任Advaxis, Inc.首席财务官和公司秘书。从2008年5月到2013年8月，她担任VirtualScopics, Inc.（制药、生物技术和医疗设备行业的成像解决方案上市供应商）的业务和财务总监和高级副总裁。从2003年5月到2008年5月，她担任公司的首席财务官。主要职责包括提供战略方向、监督所有战略、合同、法律、知识产权、商业和金融相关的问题，以及确保遵守金融和证券交易委员会报告要求。此外，她负责公司的投资者关系，准备和协调所有VirtualScopics公司的外部通信，包括新闻公告。她经常访问纽约和美国其它主要城市，进行路演以及频繁的公司演讲、公司的技术关键生命科学投资者会议。从2013年到2015年，她的家人搬到了欧洲。职业生涯早期，她担任Ultralife, Inc.（上市高性能锂电池解决方案供应商）的公司财务总监。任职Ultralife之前，她曾担任PricewaterhouseCoopers LLP的审计部门经理。她获得the State University of New York（位于水牛城）的学士学位和工商管理硕士学位。
- Molly Henderson was appointed as Advaxis, Inc. Chief Financial Officer, Executive Vice President and Corporate Secretary in June 2018. Prior to assuming her position at Advaxis, Ms. Henderson was a freelance consultant, as well as the Chairman and partial owner of WUJU, LLC, a consumer products company, from August 2016 to June 2018. Prior to that, Ms. Henderson was Chief Financial Officer at Iovance Biotherapeutics, Inc. formerly Lion Biotechnologies, Inc. from June 2015 through August 2016. Ms. Henderson also served as the Chief Business and Financial Officer, Senior Vice President of VirtualScopics, Inc., a public company provider of imaging solutions to the pharmaceutical, biotechnology, and medical device industries, from May 2008 to August 2013 and as that company's Chief Financial Officer from May 2003 to May 2008. From 2013 to 2015 Ms. Henderson relocated her family to Europe, during which time Ms. Henderson advised start-up companies in Switzerland. Earlier in her career, Ms. Henderson served as the Corporate Controller of Ultralife, Inc., a publicly-held provider of high performance lithium battery solutions. Prior to Ultralife, Ms. Henderson was a Manager in the audit division of PricewaterhouseCoopers LLP. Ms. Henderson received her M.B.A. and B.S. degrees from the State University of New York at Buffalo.
- Kenneth Berlin
Kenneth Berlin自2018年4月起担任我们的总裁兼首席执行官兼董事会成员。在加入Advaxis之前，Berlin先生自2009年11月起担任Rosetta Genomics的总裁兼首席执行官。在加入Rosetta Genomics之前，Berlin先生是强生公司公司Veridex，LLC的全球总经理。在Veridex，随着Veridex从研发实体过渡到肿瘤诊断产品和服务的商业提供商，他将公司发展到100多名员工，推出了三种癌症诊断产品，领导了对其细胞诊断合作伙伴的收购，并实现了销售的大幅增长。Berlin先生于1994年加入强生公司，并担任了6年的公司法律顾问。从2001年到2004年，他曾担任Pharmaceuticals Group的Vice President、许可和新业务开发，从2004年到2007年，他曾担任Ortho-Clinical Diagnostics公司的全球Vice President、特许经营开发。Berlin先生拥有普林斯顿大学（Princeton University）的A.B.学位和加州大学洛杉矶分校（University of California Los Angeles School of Law）的法学博士学位。
Kenneth Berlin has served as our President and Chief Executive Officer and a member of our Board of Directors since April 2018. Prior to joining Advaxis, Mr. Berlin served as President and Chief Executive Officer of Rosetta Genomics since November 2009. Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. At Veridex he grew the organization to over 100 employees, launched three cancer diagnostic products, led the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from an R&D entity to a commercial provider of oncology diagnostic products and services. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics. Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.- Kenneth Berlin自2018年4月起担任我们的总裁兼首席执行官兼董事会成员。在加入Advaxis之前，Berlin先生自2009年11月起担任Rosetta Genomics的总裁兼首席执行官。在加入Rosetta Genomics之前，Berlin先生是强生公司公司Veridex，LLC的全球总经理。在Veridex，随着Veridex从研发实体过渡到肿瘤诊断产品和服务的商业提供商，他将公司发展到100多名员工，推出了三种癌症诊断产品，领导了对其细胞诊断合作伙伴的收购，并实现了销售的大幅增长。Berlin先生于1994年加入强生公司，并担任了6年的公司法律顾问。从2001年到2004年，他曾担任Pharmaceuticals Group的Vice President、许可和新业务开发，从2004年到2007年，他曾担任Ortho-Clinical Diagnostics公司的全球Vice President、特许经营开发。Berlin先生拥有普林斯顿大学（Princeton University）的A.B.学位和加州大学洛杉矶分校（University of California Los Angeles School of Law）的法学博士学位。
- Kenneth Berlin has served as our President and Chief Executive Officer and a member of our Board of Directors since April 2018. Prior to joining Advaxis, Mr. Berlin served as President and Chief Executive Officer of Rosetta Genomics since November 2009. Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. At Veridex he grew the organization to over 100 employees, launched three cancer diagnostic products, led the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from an R&D entity to a commercial provider of oncology diagnostic products and services. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics. Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.
- Andres Gutierrez
Andres Gutierrez自2018年4月起担任我们的执行Vice President兼首席医疗官。在加入Advaxis之前，Gutierrez博士于2016年11月至2018年4月担任Oncolytics Biotech，Inc.的首席医疗官。在Oncolytics之前，Gutierrez博士于2015年11月至2016年9月担任Sellas Life Sciences Group的首席医疗官，并担任医疗总监，2012年10月至2015年11月，他在百时美施贵宝（Bristol-Myers Squibb）早期开发免疫肿瘤学，在那里他负责实体瘤和血液恶性肿瘤免疫肿瘤学计划的转化和临床开发。早些时候，Gutierrez博士是几家生物技术公司的医学总监，包括Sunesis Pharmaceuticals，Biomarin Pharmaceutical，Proteolix和Oculus Innovative Sciences，领导Talazoparib和Carfilzomib等的关键项目。任职Oculus公司之前，他曾担任墨西哥城the National Institutes of Health的基因和细胞治疗单位的董事，以及the Hospital Angeles del Pedregal的顾问医师。
Andres Gutierrez has served as our Executive Vice President and Chief Medical Officer since April 2018. Prior to joining Advaxis, Dr. Gutierrez served as Chief Medical Officer for Oncolytics Biotech, Inc. from November 2016 to April 2018. Prior to Oncolytics, Dr. Gutierrez was Chief Medical Officer at SELLAS Life Sciences Group from November 2015 to September 2016 and was Medical Director, Early Development Immuno-Oncology at Bristol-Myers Squibb from October 2012 to November 2015 where he oversaw the development of translational and clinical development of immuno-oncology programs in solid tumors and hematological malignancies. Earlier, Dr. Gutierrez was Medical Director for several biotechnology companies including Sunesis Pharmaceuticals, BioMarin Pharmaceutical, Proteolix and Oculus Innovative Sciences, leading key programs with talazoparib and carfilzomib, among others. Prior to Oculus, he served as Director of the Gene & Cell Therapy Unit at the National Institutes of Health in Mexico City and as a consultant physician at the Hospital Angeles del Pedregal.- Andres Gutierrez自2018年4月起担任我们的执行Vice President兼首席医疗官。在加入Advaxis之前，Gutierrez博士于2016年11月至2018年4月担任Oncolytics Biotech，Inc.的首席医疗官。在Oncolytics之前，Gutierrez博士于2015年11月至2016年9月担任Sellas Life Sciences Group的首席医疗官，并担任医疗总监，2012年10月至2015年11月，他在百时美施贵宝（Bristol-Myers Squibb）早期开发免疫肿瘤学，在那里他负责实体瘤和血液恶性肿瘤免疫肿瘤学计划的转化和临床开发。早些时候，Gutierrez博士是几家生物技术公司的医学总监，包括Sunesis Pharmaceuticals，Biomarin Pharmaceutical，Proteolix和Oculus Innovative Sciences，领导Talazoparib和Carfilzomib等的关键项目。任职Oculus公司之前，他曾担任墨西哥城the National Institutes of Health的基因和细胞治疗单位的董事，以及the Hospital Angeles del Pedregal的顾问医师。
- Andres Gutierrez has served as our Executive Vice President and Chief Medical Officer since April 2018. Prior to joining Advaxis, Dr. Gutierrez served as Chief Medical Officer for Oncolytics Biotech, Inc. from November 2016 to April 2018. Prior to Oncolytics, Dr. Gutierrez was Chief Medical Officer at SELLAS Life Sciences Group from November 2015 to September 2016 and was Medical Director, Early Development Immuno-Oncology at Bristol-Myers Squibb from October 2012 to November 2015 where he oversaw the development of translational and clinical development of immuno-oncology programs in solid tumors and hematological malignancies. Earlier, Dr. Gutierrez was Medical Director for several biotechnology companies including Sunesis Pharmaceuticals, BioMarin Pharmaceutical, Proteolix and Oculus Innovative Sciences, leading key programs with talazoparib and carfilzomib, among others. Prior to Oculus, he served as Director of the Gene & Cell Therapy Unit at the National Institutes of Health in Mexico City and as a consultant physician at the Hospital Angeles del Pedregal.
- Robert G. Petit
Robert G. Petit， 2010年10月加入Advaxis公司，现任执行副总裁兼首席科学官。佩蒂特博士拥有23年所有医疗和科研方面的药物开发的经验。他曾带领发现、转化发展和知识产权发展的项目，并设计和实施从第一期至第四期的美国和国际临床评估计划。佩在加盟Advaxis公司之前，他任职于百时美施贵宝公司，负责美国医学战略铅的易普利姆玛程序，担任新肿瘤科产品医疗战略的总监和全球临床研究的主任。在加入百时美施贵宝公司之前，罗伯特曾担任MGI制药公司和Aesgen公司的临床开发副总裁。他的科学重点在于开发免疫疗法，特别强调对肿瘤免疫治疗。罗伯特已经有显著的FDA经验，并对5个新药申请/生物制品许可申请做出了贡献。佩蒂特博士拥有美国俄亥俄州立大学医学院的博士学位和印第安纳州立大学的学士学位。
Robert G. Petit joined Advaxis in October 2010 and currently serves as Executive Vice President and Chief Scientific Officer, a position he has held since May 2013. Prior to serving as our Chief Scientific Officer, Dr. Petit served as our Vice President of Clinical Operations and Medical Affairs since October 2010. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV. Dr. Petit joined Advaxis from Bristol Myers Squibb where he was the U.S. Medical Strategy Lead for the Ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr. Petit has a Doctorate from the Ohio State University College of Medicine and a B.S. from Indiana State University.- Robert G. Petit， 2010年10月加入Advaxis公司，现任执行副总裁兼首席科学官。佩蒂特博士拥有23年所有医疗和科研方面的药物开发的经验。他曾带领发现、转化发展和知识产权发展的项目，并设计和实施从第一期至第四期的美国和国际临床评估计划。佩在加盟Advaxis公司之前，他任职于百时美施贵宝公司，负责美国医学战略铅的易普利姆玛程序，担任新肿瘤科产品医疗战略的总监和全球临床研究的主任。在加入百时美施贵宝公司之前，罗伯特曾担任MGI制药公司和Aesgen公司的临床开发副总裁。他的科学重点在于开发免疫疗法，特别强调对肿瘤免疫治疗。罗伯特已经有显著的FDA经验，并对5个新药申请/生物制品许可申请做出了贡献。佩蒂特博士拥有美国俄亥俄州立大学医学院的博士学位和印第安纳州立大学的学士学位。
- Robert G. Petit joined Advaxis in October 2010 and currently serves as Executive Vice President and Chief Scientific Officer, a position he has held since May 2013. Prior to serving as our Chief Scientific Officer, Dr. Petit served as our Vice President of Clinical Operations and Medical Affairs since October 2010. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV. Dr. Petit joined Advaxis from Bristol Myers Squibb where he was the U.S. Medical Strategy Lead for the Ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr. Petit has a Doctorate from the Ohio State University College of Medicine and a B.S. from Indiana State University.